Board of Directors

Shareholdings are correct as at May 31 2021, and are updated every year.

Bert Junno

Chairman of the board since 2020

Born: 1966

Education and experience: Bert has previous management and board level experiencefrom several European and US based companies in fields of electronics, biotech and IT. He is a co-founder of several life science companies including WntResearch AB, Galecto Biotech AB, Gabather AB, Aptahem AB and Cyxone AB. Bert Junno holds a Ph.D. in Semiconductor Physics and Technology and a M.Sc. in Physics from Lund University.

Current assignments: Chairman of the Board of Cyxone AB (publ). Board member of Accequa AB and Accequa GmbH.

Previous assignments: Board member of Taurus Energy AB (publ), Cardiovax llc., Galecto Biotech AB, Aptahem AB (publ), CEO and Board member of WntResearch AB (publ) and Gabather AB (publ). Member of the advisory board of the Swedish patent office 2010-2019.

Own and/or related parties’ holdings in the company: Holds no shares or warrants.

Independent of the company and the management, independent of the major owners of the company.

Gunilla Lundmark

Boardmember since 2021


Education and experience: Gunilla has broad experience in life science, from both operational operations as well as strategic positions and various board assignments. Gunilla is currently CEO of Uppsala University Invest AB and has previously been CEO of Pharmanest AB, a company where she has been part of developing a new product in women’s health, which has resulted in a successful outlicensing agreement. Gunilla has also held senior positions within Q-Med AB (publ) in Sweden and Australia, as well as within Pharmacia. Gunilla holds a B.Sc in Medical Science from Uppsala University and an Excecutive MBA degree in International Business Management from Uppsala University.

Current assignmentsHolds board positions within Chordate Medical Holding AB (publ.), IPF AB. Lipidor AB (publ.), Uppsala Innovation Centre AB, Uppsala University Project AB and Uppsala University Research Intellectual Property AB.

Previous assignments: Uppsala Akademistall AB Exscale, Biospecim Solutions AB and AddBio AB.AB.

Own and/or related parties’ holdings in the company: Holds no shares or warrants.

Independent in relation to the company and company management and to the company’s major Shareholders.

Peter Nilsson

Board member since 2014

Born: 1970

Education and experience: Peter has a long background in finance and is currently working as a CFO with a focus on strategic and business development in the Rotorbulk Group, also known as Finja. Previously,Peter was a partner and business area manager at Mazars SET Revisionsbyrå AB. As an auditor, Peter has worked with both owner-managed and public companies, and has conducted exchange audits prior to listing on the NGM stock exchange. He was also director of Corporate Finance at Mazars, focusing on acquisitions and due diligence. Peter received his M.Sc. in Business Administration and Economics from Lund University and was a certified public auditor.

Current assignments: Board member and owner of PN Finanskonsult AB and Chairman of the Board of Flisby AB.

Previous assignments: Board member of VA Automotive AB (publ) and Chairman of the Board of Åhus Åkeri AB.

Own and/or related parties’ holdings in the company: 77 227 shares.

Independent of the company and the management, independent of the major owners of the company.

Jonas Ekblom

Board member since 2020

Born: 1965

Education and experience: Jonas has worked over 25 years in the life science sector. He is currently the
CEO of Promore Pharma and has previously held senior and executive roles in biotech companies in Sweden, US and Switzerland including Pharmacia, Biovitrum, Sequenom and Invitrogen and BOWS Pharmaceuticals SA. He is an Associate Professor in Pharmacology at Uppsala University, has a B.Sci. in Chemistry from Stockholm
University, a Ph.D. in Experimental Neurology from Uppsala University, and post-doctoral studies from University of Southern California, School of Pharmacy in LA. He has also received professional training in strategic planning and business management. Jonas has published more than 60 articles in peer-reviewed journals.

Current assignments: CEO of Promore Pharma AB (publ). Board director in World 5 Ventures and Pergamum AB. Chairman of the board in EffRx Pharmaceuticals SA. Edge of the World Strategies Corporation (own consultancy company).

Previous assignments: Board director in Orin Pharmaceuticals SA, KLIFO A/S, Axelar AB and The Releef Initiative.

Own and/or related parties’ holdings in the company: Holds no shares or warrants.

Independent of the company and the management, independent of the major owners of the company.

Per Lundin

Board member since 2020

Born: 1983

Education and experience: Per has over 10 years of experience in advising, founding and leading biotech companies, leveraging his deep expertise across corporate strategy, scientific leadership, legal &intellectual property and business development. Per is co-founder and COO of UK-based Evox Therapeutics. Prior to founding Evox, Per co-founded and served as CEO of IsletOne Therapeutics, a cell therapy company spun out of the Karolinska Institute. Previously, Per managed a European business development channel for Thomson Reuters IP & Science and before that qualified as a European Patent Attorney, starting out in the biotech practice of one of the largest European IP law firms. He started his career as a research scientist with the Australian biotech company Apollo Life Sciences, working on nanoparticle drug delivery. Per earned his Ph.D. at the Karolinska Institute, holds an MSc in Biotechnology Engineering, and an MScBA from Stockholm University School of Business.

Current assignments: Board member of Evox Therapeutics Ltd.

Previous assignments:COO in Evox Therapeutics Ltd and Board member in Evox Therapeutics AB

Own and/or related parties’ holdings in the company: 5 976 shares.

Independent of the company and the management, independent of the major owners of the company.

About CombiGene

CombiGene’s vision is to provide patients affected by severe life-altering diseases with the prospect of a better life through novel gene therapies. CombiGene’s business concept is to develop effective gene therapies for severe life-altering diseases where adequate treatment is currently lacking. Development assets are sourced from an external research network and developed to achieve clinical proof of concept. Drug candidates for common diseases will be co-developed and commercialized through strategic partnerships, while the company may manage this process on its own for drugs targeting niched patient populations.

The Company has an exclusive collaboration and licensing agreement for the CG01 project with Spark Therapeutics.

The company is public and listed on the Swedish marketplace Nasdaq First North Growth Market and the company’s Certified Advisor is FNCA Sweden AB, +46 (0)852 80 03 99



CombiGene AB, Agavägen 52A, SE-181 55 Lidingö


Linked In     Twitter      Facebook